A modified protocol of the alloxan technique for the induction of diabetes mellitus in Wistar rats by Abboud, Renato de Souza et al.
Medicina Veterinária (UFRPE) 
 
Received: 14 February 2019. Accepted: 28 September 2020. 





A modified protocol of the alloxan technique for the induction of diabetes mellitus in Wistar 
rats 
 
[Protocolo modificado de indução à diabetes mellitus por aloxana em ratos Wistar] 
 
“Short Communication/Comunicação Breve” 
 
Renato de Souza Abboud1, Mauricio Alves Chagas1*, Ilma Cely de Amorim Ribeiro1, Lanna 
Beatriz Neves Silva Corrêa1, Raquel Milhomem Lange2 
 
 
1Universidade Federal Fluminense, Niterói-RS, Brasil. 
2Universidade Castelo Branco, Rio de Janeiro-RJ, Brasil. 




The chemical induction of diabetes mellitus in Wistar rats using alloxan is a commonly adopted scientific 
method for obtaining experimental models. Although a wide variety of induction protocols have been 
reported, no standard protocol has been defined due to high mortality rates, reversal, and failure of induction. 
Therefore, this study proposes an adaptation of the technique to induct diabetes mellitus through a 30-hour 
fast and a 150 mg/kg dosage of alloxan. The proposed technique has proved to be highly effective. 
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Resumo 
A indução química ao diabetes mellitus em ratos Wistar usando aloxana é um método científico usualmente 
utilizado para a obtenção de modelos experimentais. Grande variedade de protocolos de indução são 
reportados na literatura, no entanto, não há um protocolo padrão adotado devido às altas taxas de 
mortalidade, reversibilidade e falha na indução. Portanto, este estudo propõe uma adaptação da técnica de 
indução ao diabetes, adotando um jejum de 30 horas e uma dosagem de 150mg/kg a fim de obter alta 
eficiência. 
Palavras-chave: hiperglicemia; diabetes experimental; indução química; protocolo de aloxana. 
 
 
The chemical induction of diabetes mellitus 
in Wistar rats by using cytotoxic drugs to produce 
experimental animal models is still widely 
practiced (Zanoello et al., 2002; Ribeiro et al., 
2007). The diabetogenic properties of alloxan 
have been studied since 1943 when Dunn et al. 
(1943) examined the effect of its administration 
on rabbits and reported specific necrosis in the 
pancreatic islets. However, there is no standard 
protocol for the induction of diabetes, and the 
existing techniques present high mortality rates, 
reversion, and failure of induction due to the 
chemical instability of the drug. Rapid 
metabolism and factors such as diet, weight, and 
age, make it difficult to establish the dosage of 
alloxan that would be most effective in the 
pancreas (Federiuk et al., 2004; Negri, 2005; 
Ribeiro et al., 2007).  
The application of alloxan 
intravenously/intraperitoneally selectively 
destroys pancreatic β cells since its molecule is 
similar to a glucose molecule as it is captured by 
the glucose transporter GLUT2, which is present 
in the plasma of the β-cell membrane, and it is 
transported to the cytosol, thereby promoting a 
massive release of insulin (Szkudelski et al., 1998; 
Lima et al., 2001; Szkudelski, 2001). 
Through a redox reaction, alloxan begins to 
produce a reactive oxygen species (free radicals), 
thus initiating toxic damage to β-cells (Lenzen, 
2008). The action of alloxan on β cells is initiated 
when the hydroxyl radicals affect the oxidative 
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metabolism of the cells with subsequent selective 
necrosis of the β cells and cell deaths, which 
causes a state of insulin-dependent diabetes 
(Zanoello et al., 2002; Lenzen, 2008). β-cells 
exhibit a higher sensitivity to peroxide radicals 
when compared to other tissues because of the 
low activity of GSH peroxidase, which catalyzes 
the reduction of peroxides in these cells (Lima et 
al., 2001; Szkudelski, 2001; Cavalli et al., 2007).  
Different animal species can be used as 
models of diabetes mellitus after being induced 
with alloxan, including rats, dogs, rabbits, 
hamsters, guinea pigs, and even sheep (Lerco et 
al., 2003; Federiuk et al., 2004).  
Young (55-day old) male Wistar Furth rats 
provided by the Laboratory Animal Center 
(NAL/UFF), were used for the induction of 
diabetes. These animals were housed in individual 
cages in a controlled environment with respect to 
temperature, humidity, and noise, and they were 
fed pelleted commercial feed (Nuvilab®) ad 
libitum. The induction process was initiated with a 
30-hour feed restriction for the animals, during 
which the animals received no food but received 
water at will. After the fasting period, the animals 
were manually restrained and received an 
intraperitoneal injection of monohydrate alloxan, 
+ 98% (Cayman Chemical, code 9002196), which 
was previously diluted in a solution of 0.9% 
sodium chloride (at a ratio of 600 mg of alloxan in 
40 mL of the saline solution). From this solution, 
at 1.5%, a volume of 1 mL per 100 grams of live 
weight was applied with a 25×6 needle in the 
lower right abdominal quadrant after the animal 
was properly contained. Subsequently, the rats 
were re-housed in their cages with water and 
commercial feed ad libitum. 
The glycemia of all the rats was measured 3 
days after the administration of alloxan, after 
establishing a 6-hour fast. One drop of blood was 
withdrawn by puncturing the tail of the animals 
with the aid of a stylus and by using a OneTouch 
Ultra blood glucose meter (Johnson & Johnson 
Company, USA) to analyze the glycemia of the 
animals. All the animals that presented glycemic 
levels equal to or greater than 270 mg/dl were 
considered to be diabetic and included in the 
experiment (Moustafa et al., 2004). The 
experimentation on the animals in the animal 
facility continued for 60 days, during which the 
glycemic levels, food intake, and body weight 
evolution of all the animals were evaluated. No 
animals died after induction or during the 
subsequent period of experimentation. No cases of 
reversal were observed. 
In the induction protocols, intravenous (iv) 
alloxan is often administered to rats at a dose of 
40 to 65 mg/kg (Szkudelski, 2001; Carvalho et al., 
2003; Lerco et al., 2003; Cavalli et al., 2007). 
However, when administered intraperitoneally or 
subcutaneously, the effective dose is usually two 
to three times higher (Szkudelski, 2001).  
The analysis of glycemia was used to 
control the efficiency of alloxan in the destruction 
of the β cells of the pancreas. 
The administration of alloxan caused an 
increase in blood glucose levels in the first week 
following the application of the drug, and this 
increase was maintained over 8 weeks (Figure 1). 
The findings of this study show the effectiveness 
of the 150 mg/kg dose administered 
intraperitoneally to rats. There was no mortality 





Figure 1. Evolution of blood glucose levels after 
induction with alloxan. Note that the levels 
remain high until the end of the 
experiment. 
 
Szkudelski (2001), in his study, 
demonstrated that an intraperitoneal dose below 
150mg/kg might be insufficient to induce diabetes 
in rats, thereby raising the requirement of a 
second dose. Silva et al. (2014) reported that a 
dose of 200 mg/kg administered intraperitoneally 
results in a high percentage of diabetic animals. 
However, it causes a higher mortality rate when 
compared to doses lower than 80 mg/kg and 120 
mg/kg. Federiuk et al. (2004) studied several 
protocols of diabetes induction and found that a 
dose of 200 mg/kg of alloxan administered 
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intraperitoneally in a group of 10 animals with 
diabetes killed one animal during the first week. 
In the present study, the 150 mg/kg dose at a 1.5% 
dilution was administered intraperitoneally with a 
30-hour fast. It effectively led to an increase in the 
glycemic characteristic of the disease in several 
animals without post-induction deaths and 
reversion. The efficacy of alloxan is directly 
proportional to the time taken for the fast 
(Zanoello et al., 2002; Lerco et al., 2003; Federiuk 
et al., 2004; Cavalli et al., 2007). In a study by 
Silva and Nogueira (2015), a 24-hour fast along 
with a dose of 150mg/kg of alloxan proved a 
reduction in the number of diabetic animals—a 
reversal had occurred. The animals had become 
hyperglycemic on the 7th day and normoglycemic 
on the 14th day. The production of animal models 
for the study of metabolic diseases is essential for 
the development of new therapies. The refinement 
of the diabetes induction technique reported in 
this study has greatly increased the efficiency of 
the method by reducing the failure and mortality 
rates. Therefore, researchers can safely decrease 
the use of animals in their experiments and 
contribute to future studies and the development 
of new drugs in accordance with two of the items 
included in the humanitarian principles of animal 
experimentation: reduction and refinement. 
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